

Tomasz Sewastianik

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9385503/publications.pdf>

Version: 2024-02-01

39
papers

775
citations

759233

12
h-index

526287

27
g-index

39
all docs

39
docs citations

39
times ranked

1900
citing authors

#	ARTICLE	IF	CITATIONS
1	A novel β -catenin/BCL9 complex inhibitor blocks oncogenic Wnt signaling and disrupts cholesterol homeostasis in colorectal cancer. <i>Science Advances</i> , 2022, 8, eabm3108.	10.3	10
2	A hotspot mutation in transcription factor IKZF3 drives B cell neoplasia via transcriptional dysregulation. <i>Cancer Cell</i> , 2021, 39, 380-393.e8.	16.8	27
3	<i>miR-15a/16-1</i> deletion in activated B cells promotes plasma cell and mature B-cell neoplasms. <i>Blood</i> , 2021, 137, 1905-1919.	1.4	8
4	ROBO1 Promotes Homing, Dissemination, and Survival of Multiple Myeloma within the Bone Marrow Microenvironment. <i>Blood Cancer Discovery</i> , 2021, 2, 338-353.	5.0	8
5	Bortezomib Induces Anti-Multiple Myeloma Immune Response Mediated by cGAS/STING Pathway Activation. <i>Blood Cancer Discovery</i> , 2021, 2, 468-483.	5.0	64
6	ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment. <i>Science Advances</i> , 2021, 7, .	10.3	11
7	Aggressive CD4/CD8 Double-Negative Primary Cutaneous T-Cell Lymphoma With Dural Invasion: A Rare Presentation of Mycosis Fungoides?. <i>American Journal of Dermatopathology</i> , 2021, 43, 63-66.	0.6	0
8	The ERK1/2 Regulator WNK2 Shows Differential Expression and Isoform Usage, Primarily Driven By Aberrant Methylation, in MYD88 Mutated Waldenström's Macroglobulinemia. <i>Blood</i> , 2021, 138, 2692-2692.	1.4	0
9	BCL9 provides multi-cellular communication properties in colorectal cancer by interacting with paraspeckle proteins. <i>Nature Communications</i> , 2020, 11, 19.	12.8	27
10	Multicenter phase 2 study of daratumumab monotherapy in patients with previously treated Waldenström macroglobulinemia. <i>Blood Advances</i> , 2020, 4, 5089-5092.	5.2	5
11	Multiplexed CRISPR <i>In Vivo</i> Editing of CLL Loss-of-Function Lesions Models Transformation of Chronic Lymphocytic Leukemia into Richter's Syndrome. <i>Blood</i> , 2020, 136, 2-3.	1.4	1
12	Human MYD88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells. <i>Blood Advances</i> , 2019, 3, 3360-3374.	5.2	25
13	Oncogenic activity of human MYD88L265P mutation in mature B-cells <i>in vivo</i> . <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e331.	0.4	0
14	B Cell Restricted Expression of Mutated IKZF3 modulates BCR Signaling and Homing Pathways in a Mouse Model of CLL. <i>Blood</i> , 2019, 134, 848-848.	1.4	0
15	Microenvironment-induced PIM kinases promote CXCR4-triggered mTOR pathway required for chronic lymphocytic leukaemia cell migration. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 3548-3559.	3.6	17
16	Nanoparticles for Immune Cytokine TRAIL-Based Cancer Therapy. <i>ACS Nano</i> , 2018, 12, 912-931.	14.6	107
17	Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma. <i>Cell</i> , 2018, 175, 101-116.e25.	28.9	234
18	A novel, dual pan-PIM/FLT3 inhibitor SEL24 exhibits broad therapeutic potential in acute myeloid leukemia. <i>Oncotarget</i> , 2018, 9, 16917-16931.	1.8	25

#	ARTICLE	IF	CITATIONS
19	Expression of PIM kinases in Reed-Sternberg cells fosters immune privilege and tumor cell survival in Hodgkin lymphoma. <i>Blood</i> , 2017, 130, 1418-1429.	1.4	42
20	MiR-17-92 represses PTPROt and PP2A phosphatases and amplifies tonic BCR signaling in DLBCL cells. <i>Experimental Hematology</i> , 2017, 46, 56-61.e1.	0.4	13
21	Constitutive Ras signaling and Ink4a/Arf inactivation cooperate during the development of B-ALL in mice. <i>Blood Advances</i> , 2017, 1, 2361-2374.	5.2	11
22	Abstract 4087: Development of a potent, dual pan-PIM/FLT3 inhibitor for the treatment of heme malignancies. , 2017, , .		0
23	FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas. <i>Blood</i> , 2016, 127, 739-748.	1.4	54
24	Microenvironment-Induced Expression of PIM Kinases Supports Chronic Lymphocytic Leukemia Cells Survival and Promotes CXCR4-mTOR Pathway Dependent Migration. <i>Blood</i> , 2016, 128, 3239-3239.	1.4	4
25	MEK Inhibition Sensitizes Precursor B-Cell Acute Lymphoblastic Leukemia (B-ALL) Cells to Dexamethasone through Modulation of mTOR Activity and Stimulation of Autophagy. <i>PLoS ONE</i> , 2016, 11, e0155893.	2.5	26
26	Functional Link Between Heat Shock Protein HSP90alpha and Sirtuin 1 (SIRT1) in the Pathogenesis of Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2016, 128, 4120-4120.	1.4	0
27	Downregulation of Deptor By MiR-155 Promotes Cell Survival through Activation of PI3K/AKT and NFkB Signaling in ABC-Type Diffuse Large B-Cell Lymphomas. <i>Blood</i> , 2016, 128, 1761-1761.	1.4	2
28	Germinal Center-Derived Lymphomas and Plasmacytomas in Mice with Targeted Deletion of MiR-15a/16-1 in Activated B Cells. <i>Blood</i> , 2016, 128, 743-743.	1.4	0
29	Overexpression of BCL9, a Wnt/ β 2-Catenin Transcriptional Co-Activator, in Transgenic Mice Promotes Spontaneous Development of B-Cell Malignancies. <i>Blood</i> , 2016, 128, 441-441.	1.4	0
30	MiR-155 Amplifies AKT and NFkB Signaling By Targeting Multiple Regulators of BCR Signal in DLBCL. <i>Blood</i> , 2015, 126, 2455-2455.	1.4	6
31	FOXO1-p300-Txn Circuit Regulates Oxidative Stress Responses in Diffuse Large B-Cell Lymphomas Characterized By Enhanced Oxidative Phosphorylation. <i>Blood</i> , 2015, 126, 466-466.	1.4	1
32	A Novel Pan-PIM Kinase Inhibitor, SEL24-B489, Induces Apoptosis and Inhibits Proliferation of Diffuse Large B-Cell Lymphoma Cells through Inhibition of Protein Translation and Attenuation of Myc and NFkB Activity. <i>Blood</i> , 2015, 126, 706-706.	1.4	2
33	Abstract 5394: First-in-class dual PIM/FLT3 kinase inhibitor SEL24-B489 for the treatment of hematological malignancies. <i>Cancer Research</i> , 2015, 75, 5394-5394.	0.9	1
34	HIF1-Alpha and MYC Transcription Factor Signatures in B-Cell Acute Lymphoblastic Leukemia Are Associated with Positive Minimal Residual Disease Status: Therapeutic Implications. <i>Blood</i> , 2015, 126, 1436-1436.	1.4	0
35	Activity of PIM Kinases in Chronic Lymphocytic Leukemia Modulates Tumor Cell Survival and Stromal Interactions through a Pleiotropic Mechanism Involving Modulation of CXCR4 - mTOR Pathway. <i>Blood</i> , 2015, 126, 1549-1549.	1.4	0
36	Expression of PIM Kinases in Reed-Sternberg Cells Fosters Immune Privilege and Tumor Cell Survival in Classical Hodgkin Lymphoma. <i>Blood</i> , 2015, 126, 819-819.	1.4	0

#	ARTICLE	IF	CITATIONS
37	MEK1 Inhibitor Selumetinib Sensitizes Precursor B-Cell Acute Lymphoblastic Leukemia Cells (B-ALL) to Dexamethasone through Modulation of mTOR Activity and Stimulation of Autophagy. <i>Blood</i> , 2015, 126, 4917-4917.	1.4	0
38	MYC deregulation in lymphoid tumors: molecular mechanisms, clinical consequences and therapeutic implications. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1846, 457-467.	7.4	42
39	Abstract 1749: Preclinical characterization of SEL24-B489, a dual PIM/FLT3 inhibitor for the treatment of hematological malignancies. <i>Cancer Research</i> , 2014, 74, 1749-1749.	0.9	2